deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03618758

Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 (IPLUS)

Safety and Efficacy of Intraperitoneal Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis Receiving Systemic Chemotherapy

Sponsor: B. Braun Korea Co., Ltd.

Conditions Gastric Cancer Stage IV Intraperitoneal Paclitaxel Peritoneal Carcinomatosis mFOLFOX6
Interventions Paclitaxel mFOLFOX6 regimen
Updated 9 times since 2018 Last updated: Dec 2, 2023 Started: Dec 24, 2018 Primary completion: Aug 31, 2023 Completion: Dec 2, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03618758, this PHASE1/PHASE2 trial focuses on Gastric Cancer Stage IV and Intraperitoneal Paclitaxel and remains completed. Sponsored by B. Braun Korea Co., Ltd., it has been updated 9 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshotRecruiting~Dec 2018 – ~Oct 2019 · 10 months · monthly snapshotRecruiting~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshotRecruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotRecruiting~Apr 2021 – ~Jan 2024 · 33 months · monthly snapshotRecruiting~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  5. Apr 2021 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Oct 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Dec 2018 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • B. Braun Korea Co., Ltd.
  • Boryung Pharmaceutical Co., Ltd
  • Seoul National University Bundang Hospital
Data source: Seoul National University Bundang Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations